Resultados de búsqueda - Andrew J. Armstrong

Limitar resultados
  1. 1
    Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer

    Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer por Emmanuel S. Antonarakis, Andrew J. Armstrong

    Publicado 2011
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

    Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer por Rhonda L. Bitting, Andrew J. Armstrong

    Publicado 2013
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  3. 3
    Reply to R. Sun et al

    Reply to R. Sun et al por Andrew J. Armstrong, Brad Rosbrook, Shunsuke Yamada

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Carta
    Agregar a favoritos
    Guardado en:
  4. 4
    Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin

    Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin por Andrew J. Armstrong, Daniel J. George, Susan Halabi

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

    Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease por Michael R. Harrison, Daniel J. George, Wong, Andrew J. Armstrong

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting

    Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting por Emmanuel S. Antonarakis, Andrew J. Armstrong, Scott M. Dehm, Jun Luo

    Publicado 2016
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  7. 7
    Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations

    Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations por Changxue Lu, Landon C. Brown, Emmanuel S. Antonarakis, Andrew J. Armstrong, Jun Luo

    Publicado 2020
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  8. 8
    Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

    Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer por Kathryn E. Ware, Mariano A. Garcia‐Blanco, Andrew J. Armstrong, Scott M. Dehm

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  9. 9
    The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

    The role of epithelial plasticity in prostate cancer dissemination and treatment resistance por Rhonda L. Bitting, Daneen Schaeffer, Jason A. Somarelli, Mariano A. Garcia‐Blanco, Andrew J. Armstrong

    Publicado 2014
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  10. 10
    Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

    Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide por Krista Noonan, Scott North, Rhonda L. Bitting, Andrew J. Armstrong, Susan Ellard, K.N. Chi

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

    Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer por Andrew J. Armstrong, Elizabeth Garrett‐Mayer, Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger

    Publicado 2009
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

    Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond por Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, Tian Zhang

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  13. 13
    Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey

    Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey por Hannah D. McManus, Tanya B. Dorff, Alicia K. Morgans, Oliver Sartor, Neal D. Shore, Andrew J. Armstrong

    Publicado 2024
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  14. 14
    A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

    A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis por Andrew J. Armstrong, Elizabeth Garrett‐Mayer, Yi-Chun Ou Yang, Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger

    Publicado 2007
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  15. 15
    Molecular determinants for enzalutamide-induced transcription in prostate cancer

    Molecular determinants for enzalutamide-induced transcription in prostate cancer por Fuwen Yuan, William Hankey, Dayong Wu, Hongyan Wang, Jason A. Somarelli, Andrew J. Armstrong, Jiaoti Huang, Zhong Chen, Qianben Wang

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    New and Emerging Therapies for Bone Metastases in Genitourinary Cancers

    New and Emerging Therapies for Bone Metastases in Genitourinary Cancers por Philip J. Saylor, Andrew J. Armstrong, Karim Fizazi, Stephen J. Freedland, Fred Saad, Matthew R. Smith, Bertrand Tombal, Kenneth J. Pienta

    Publicado 2012
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  17. 17
    Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

    Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer por Andrew J. Armstrong, Mario A. Eisenberger, Susan Halabi, Stéphane Oudard, David M. Nanus, Daniel P. Petrylak, Oliver Sartor, Howard I. Scher

    Publicado 2011
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  18. 18
    Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

    Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy por Susan Halabi, Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Ellen B. Kaplan, Chen‐Yen Lin, Nicole Solomon, Eric J. Small

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma

    Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma por Matthew Labriola, Kristen A. Batich, Jason Zhu, Megan McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Tian Zhang

    Publicado 2019
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  20. 20
    Novel therapies are changing treatment paradigms in metastatic prostate cancer

    Novel therapies are changing treatment paradigms in metastatic prostate cancer por Eric R. Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang

    Publicado 2020
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: